Back

A novel chemogenomic screening platform for scalable antimalarial drug target identification

Bower-Lepts, C. A.; Rawat, M.; Keith, W. C.; Girling, G.; Luth, M. R.; Carolino, K.; Boroviak, K.; Coyle, R.; Schwach, F.; Smidt, C.; Bushell, E.; Moliner-Cubel, S.; Gomez-Lorenzo, M. D. G.; Gamo, F.-J.; Winzeler, E. A.; Billker, O.; Lee, M. C.; Rayner, J. C.

2024-08-27 microbiology
10.1101/2024.08.27.609875 bioRxiv
Show abstract

Large-scale chemical-genetic screening, or chemogenomics, can faciliate rapid and scalable drug target identification. To establish a chemogenomic screen for antimalarial drug target identification, we leveraged [~]600 Plasmodium berghei artificial chromosomes (PbACs) encoding potential drug targets to generate a systematic overexpression library. PbACs were engineered with DNA barcodes, enabling their quantification within mixed pools using next generation sequencing (barcode sequencing or BarSeq). Pooled transfection of PbACs into the highly genetically tractable Plasmodium knowlesi demonstrated efficient vector uptake and transcription of encoded P. berghei genes. Parasite pools were exposed to antimalarial candidates, with pilot screens probing for known gene-compound associations identifying their targets with high sensitivity. Screening antimalarial inhibitors with unknown mechanisms of action successfully identified pi4k as the target for one novel compound, which was subsequently validated using in vitro evolution in Plasmodium falciparum parasites. This sensitive and scalable chemogenomics platform therefore represents a valuable early-stage tool for antimalarial target identification.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.